CAMP4 Therapeutics Corporation (CAMP) Investor Relations Documents

CAMP4 Therapeutics Corporation (CAMP) investor relations documents from the company's IR site: 6 presentations, 26 press releases; latest deck 2026-08-13. Read in-app with summaries. First-party data.

Download PDF: CAMP4 is developing RNA medicines, starting with CMP-002 for SYNGAP1 disorder, with a Phase 1/2 study in Q4 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13PresentationDownload PDF
2026-08-13Press releasePDF Version
2026-08-13Press releaseCAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-04Press releasePDF Version
2026-08-04Press releaseCAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
2026-07-27Press releasePDF Version
2026-07-27Press releaseCAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patie
2026-07-17Press releasePDF Version
2026-07-17Press releaseCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-06-19Press releasePDF Version
2026-06-19Press releaseCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-21Press releasePDF Version
2026-05-21Press releaseCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-14PresentationTargeting noncoding regulatory RNAs with antisense oligonucleotides to increase gene expression for the potential treatm
2026-05-14Press releasePDF Version
2026-05-14Press releaseCAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Mo
2026-05-07Press releasePDF Version
2026-05-07Press releaseCAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-04-28Press releasePDF Version
2026-04-28Press releaseCAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
2026-04-17Press releasePDF Version
2026-04-17Press releaseCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-06Press releasePDF Version
2026-03-05Press releasePDF Version
2026-03-05Press releaseCAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
2026-01-06Press releasePDF Version
2026-01-06Press releaseCAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-09-25PresentationDeveloping Regulatory RNA-based Therapeutics for DEEs and an ASO to Increase SYNGAP Gene Expression
2025-05-16PresentationA Phase 1 Study to Evaluate the Safety and Tolerability of an Investigational ASO (CMP-CPS-001) for the Treatment of Ure
2025-05-16PresentationTargeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of Urea Cycle Disorders
2025-05-16PresentationTargeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of SYNGAP1-Related Disorders
Press releaseCAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP overview · CAMP earnings · CAMP financials · CAMP KPIs · CAMP ownership · CAMP peers · CAMP filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.